中国视网膜母细胞瘤疾病流行及负担分析  

Analysis of the prevalence and burden of retinoblastoma in China

作　　者：祝源 陈奕嘉 周家林 刘恒志 周希瑗[1] ZHU Yuan;CHEN Yijia;ZHOU Jialin;LIU Hengzhi;ZHOU Xiyuan(Department of Ophthalmology,the Second Affiliated Hospital of Chongqing Medical University,Chongqing 400010,China;Clinical Medical College,Southwest Medical University,Luzhou 646000,Sichuan Province,China)

机构地区：[1]重庆医科大学附属第二医院眼科,重庆市400010 [2]西南医科大学临床医学院,四川省泸州市646000

出　　处：《眼科新进展》2025年第5期359-364,共6页Recent Advances in Ophthalmology

基　　金：国家自然科学基金面上项目(编号:82070976)。

摘　　要：目的通过2021全球疾病负担(GBD 2021)数据库探究中国视网膜母细胞瘤(RB)疾病流行和负担情况,为中国RB诊治提供理论依据。方法分析1990-2021年中国RB总体、男性及女性的标化发病率、标化患病率、标化死亡率、标化伤残调整寿命年(DALY)率等相关指标,评估RB流行水平和疾病负担情况;采用Joinpoint模型分析1990-2021年中国RB总体标化发病率、总体标化患病率、总体标化死亡率和总体标化DALY率的年度百分比变化(APC)和平均年度百分比变化(AAPC);比较1990-2021年中国和全球的总体标化发病率、总体标化患病率、总体标化死亡率和总体标化DALY率变化情况。结果与1990年相比,2021年中国总体、男性和女性RB标化发病率分别增加1.840倍、2.154倍和1.689倍;总体、男性和女性RB标化患病率分别增加1.876倍、2.133倍和1.701倍;总体、男性和女性标化死亡率分别降低0.679倍、0.636倍和0.714倍;总体、男性和女性标化DALY率分别降低0.652倍、0.616倍和0.676倍。Joinpoint分析显示,与1990年相比,2021年中国总体标化发病率和总体标化患病率的AAPC分别增加3.21%和3.23%;总体标化死亡率和总体标化DALY率的AAPC分别降低3.61%和3.46%。与1990年相比,全球总体标化发病率、总体标化患病率分别增加0.237倍和0.242倍;全球总体标化死亡率、总体标化DALY率分别降低0.212倍、0.195倍。结论相较于1990年,2021年中国RB总体、男性和女性的标化发病率和标化患病率增加,标化死亡率和DALY率降低,说明疾病流行增加但负担减轻。1990-2021年间,中国总体标化发病率和总体标化患病率与全球差距先扩大再缩小,但总体标化死亡率和总体标化DALY率始终低于全球水平。Objective To investigate the prevalence and burden of retinoblastoma(RB)in China based on the Global Burden of Disease Study 2021(GBD 2021),thus providing a theoretical foundation for the diagnosis and treatment of RB.Methods Relevant indicators such as the standardized incidence rate,standardized prevalence rate,standardized mortality rate,and standardized disability-adjusted life year(DALY)rate of RB in the total population,males,and females in China from 1990 to 2021 were analyzed to assess the prevalence and disease burden of this disease.The Joinpoint model was employed to analyze the annual percent change(APC)and the average annual percent change(AAPC)of the overall standardized incidence rate,overall standardized prevalence rate,overall standardized mortality rate,and overall standardized DALY rate of RB in China from 1990 to 2021.In addition,the changes in the overall standardized incidence rate,overall standardized prevalence rate,overall standardized mortality rate,and overall standardized DALY rate were compared between China and the globe from 1990 to 2021.Results Compared with 1990,the standardized incidence rate of RB in the total population,males,and females in China increased by 1.840 times,2.154 times,and 1.689 times,respectively,in 2021;the standardized prevalence rate of RB in the total population,males,and females in China increased by 1.876 times,2.133 times,and 1.701 times,respectively;the standardized mortality rate of RB in the total population,males,and females in China decreased by 0.679 times,0.636 times,and 0.714 times,respectively;the standardized DALY rate of RB in the total population,males,and females in China decreased by 0.652 times,0.616 times,and 0.676 times,respectively.Joinpoint analysis showed that compared with 1990,the APPC of the overall standardized incidence rate and the overall standardized prevalence rate in China in 2021 increased by 3.21 and 3.23,respectively;the AAPC of the overall standardized mortality rate and the overall standardized DALY rate decreased by 3.61

关 键 词：视网膜母细胞瘤 疾病负担 伤残调整寿命年 

分 类 号：R774.1[医药卫生—眼科]